Why Tigecycline Prices Vary by Brand vs. Generic
Tigecycline, sold under the brand name Tygacil by Pfizer, sees significant price differences mainly due to the availability of generics. Brand Tygacil costs around $1,000-$2,000 per 50mg vial in the US, while generic tigecycline vials range from $100-$500, depending on supplier and quantity. This gap emerged after Pfizer's patents expired, allowing multiple generics to enter the market starting in 2020.[1][2]
When Did Patents Expire and Generics Launch?
Key US patents for Tygacil (e.g., composition-of-matter patent US 7,485,740) expired in June 2020, with pediatric exclusivity ending shortly after. The FDA approved the first generic in July 2020 from Hikma Pharmaceuticals, followed by others like Accord BioPharma and Gland Pharma. Pre-expiry, Tygacil held monopoly pricing; post-expiry, competition drove prices down 70-90%.[1][3]
How Do Prices Differ Across Countries?
US prices remain highest due to lack of price controls and high hospital markups—Tygacil can exceed $100/mg. In Europe, EMA-approved generics (e.g., from Accord) cost 50-80% less, around €20-50/mg. In India and China, local manufacturers like Hetero Drugs offer tigecycline at $5-20/mg, reflecting lower production costs and regulated markets.[2][4]
Why Hospital vs. Retail Prices Fluctuate
Hospitals pay negotiated rates 20-50% below list price for bulk purchases, but retail outpatient pricing spikes due to no-volume discounts. Shortages, like the 2023-2024 US recalls by Hikma for particulate contamination, temporarily raised generic prices 20-30% amid supply constraints.[5]
Factors Driving Ongoing Price Swings